P
Paula S. Curtis
Researcher at GlaxoSmithKline
Publications - 12
Citations - 1636
Paula S. Curtis is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Belimumab & Type 2 diabetes. The author has an hindex of 6, co-authored 8 publications receiving 1532 citations.
Papers
More filters
Journal ArticleDOI
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
Philip Home,Stuart J. Pocock,Henning Beck-Nielsen,Paula S. Curtis,Ramon Gomis,Markolf Hanefeld,Nigel P. Jones,Michel Komajda,John J.V. McMurray +8 more
TL;DR: Although the data are inconclusive about any possible effect on myocardial infarction, rosiglitazone does not increase the risk of overall cardiovascular morbidity or mortality compared with standard glucose-lowering drugs.
Journal ArticleDOI
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial
Michel Komajda,John J.V. McMurray,Henning Beck-Nielsen,Ramon Gomis,Markolf Hanefeld,Stuart J. Pocock,Paula S. Curtis,Nigel P. Jones,Philip Home +8 more
TL;DR: Findings confirm the increased risk of HF events in people treated with rosiglitazone and support the recommendation that this agent should not continue to be used in people developing symptomatic HF while using the medication.
Journal ArticleDOI
Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study)
Michel Komajda,Paula S. Curtis,Markolf Hanefeld,Henning Beck-Nielsen,Stuart J. Pocock,Andrew Zambanini,Nigel P. Jones,Ramon Gomis,Philip Home +8 more
TL;DR: Changes in BP were not accompanied by compensatory increases in heart rate, did not correlate with basal insulin sensitivity estimates and were not explained by changes in antihypertensive therapy between the various strata.
Journal ArticleDOI
Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: A substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycemia in Diabetes (RECORD) study
Michael R. MacDonald,Mark C. Petrie,Philip Home,Michel Komajda,Nigel P. Jones,Henning Beck-Nielsen,Ramon Gomis,Markolf Hanefeld,Stuart J. Pocock,Paula S. Curtis,John J.V. McMurray +10 more
TL;DR: Although the prevalence and incidence of myocardial infarction was low, unrecognized Q-wave myocardia infarctions made up a substantial proportion of all events.
Journal ArticleDOI
Sample size estimation for non-inferiority trials of time-to-event data.
Adam Crisp,Paula S. Curtis +1 more
TL;DR: An adaptation of previously developed formulae for the superiority framework is presented that specifically allows for effect reversal under the non-inferiority setting, and its consequent effect on variance.